The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide this submission for the 2018 Special 301 Report. Established by the Trade Act of 1974, the Special 301 review gives the Administration a critical tool to address damaging market access and intellectual property barriers abroad that harm America’s leading innovative and creative industries and the more than 45 million jobs they support across the country.